Upregulation of αvβ6- and/or αvβ8-mediated TGF-β activation is a driver of multiple diseases, including idiopathic pulmonary fibrosis (IPF)4–6, primary sclerosing cholangitis (PSC)7, and several solid tumors8–10, but deconvoluting the contribution of αvβ6 and αvβ8 to the etiology of these diseases has been challenging due to limitations in current interventions. This evidence concerns the gene TGFB1 and idiopathic pulmonary fibrosis.